Picture loading failed.

Pre-Made Pacmilimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pacmilimab (also known as CX 072) is a recombinant antibody prodrug composed of a monoclonal antibody, being developed by CytomX Therapeutics, for the treatment of solid tumours and breast cancer. Pacmilimab is developed using the company's ProbodyTM technology platform.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-422-1mg 1mg 3090
GMP-Bios-ab-422-10mg 10mg 21890
GMP-Bios-ab-422-100mg 100mg 148000
GMP-Bios-ab-422-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Pacmilimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
INN Name Pacmilimab
TargetCD274
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesCytomX Therapeutics
Conditions Approvedna
Conditions ActiveSolid tumours;Lymphoma
Conditions Discontinuedna
Development Techna